Home » Topics » Regulatory » EMA

EMA
RSS

FDA and EMA accept Novartis' applications for ribociclib plus letrozole in advanced breast cancer

Nov. 2, 2016

EMA accepts PharmaMar's MAA for plitidepsin

Oct. 31, 2016

Biogen gives update on regulatory applications for nusinersen in E.U., U.S.

Oct. 31, 2016

EMA accepts for review MAA for niraparib in ovarian cancer

Oct. 28, 2016

EMA issues positive opinion recommending orphan drug designation for La Jolla's LJPC-401

Oct. 25, 2016

EMA awards priority medicine designation to CymaBay Therapeutics' MBX-8025

Oct. 21, 2016

EMA gives orphan drug designation to gene therapy program ABO-102

Oct. 19, 2016

EMA grants orphan designation to Iomab-B

Oct. 19, 2016

EMA grants PRIME access to Atara's EBV-CTL

Oct. 19, 2016

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

Oct. 18, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...